Mytolac (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Mytolac, is a somatostatin analog presented as a sterile injectable solution for subcutaneous use. It treats acromegaly and hormone‑secreting neuroendocrine tumors in patients requiring hormone‑secretion control.

GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mytolac, a somatostatin analog, is used to manage conditions driven by excess hormone secretion.

Acromegaly: normalises growth‑hormone and IGF‑1 levels, reducing disease activity. Neuroendocrine tumors (carcinoid syndrome): controls hormone‑related flushing and diarrhoea. Growth‑hormone‑producing pituitary adenomas: suppresses tumour‑derived hormone release.

Mytolac may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Injection site pain or erythema - Nausea or abdominal discomfort - Diarrhoea or constipation - Headache - Fatigue - Mild hyperglycaemia

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Severe hyperglycaemia or new‑onset diabetes - Pancreatitis - Allergic reactions including anaphylaxis - Cardiac arrhythmias (rare) - Severe hepatic dysfunction

Before initiating Mytolac, clinicians should consider several safety aspects.

Monitor glucose levels: somatostatin analogues can alter blood‑sugar control. Assess gallbladder status: risk of gallstone development. Check for hypersensitivity: discontinue if severe allergic reaction occurs. Use caution in renal or hepatic impairment: dose adjustment may be required. Pregnancy and lactation: evaluate risk‑benefit ratio before prescribing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other somatostatin analogues: additive hormonal suppression. - Co‑administration with cyclosporine: potential increase in cyclosporine plasma levels.

Moderate Interactions (Monitor Closely): - Insulin and oral hypoglycaemic agents: may need dose adjustment of antidiabetic drugs. - Oral contraceptives: reduced absorption, monitor efficacy. - Medications that increase gallstone risk (e.g., estrogen therapy): monitor biliary health.